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Background: The aim of our study was to evaluate whether a panel of biomarkers, prospectively analysed might
be able to predict patients’ clinical outcome more accurately than RAS status alone.
Methods: K-RAS (exons 2, 3, 4) wild type colorectal cancer patients, candidates to second/third-line cetuximab with
chemotherapy were prospectively allocated into 2 groups on the basis of their profile: favourable (BRAF and PIK3CA
exon 20 wild type, EGFR GCN ≥ 2.6, HER-3 Rajkumar score ≤ 8, IGF-1 immunostaining < 2) or unfavourable (any of
the previous markers altered or mutated). After the introduction of N-RAS status (exons 2, 3, 4) only RAS wild type
patients were considered eligible.
Primary aim was response rate (RR). To detect a difference in terms of RR among patients with an unfavourable
profile (estimated around 25%) and patients with a favourable profile (estimated around 60%), with a probability
alpha of 0.05 and beta of 0.05, required sample size was 46 patients. Secondary endpoints were progression free
survival (PFS) and overall survival (OS).
Results: Forty-six patients were enrolled. Seventeen patients (37%) were allocated to the favourable and 29 patients
(63%) to the unfavourable profile. RR in the favourable and unfavourable group was 11/17 (65%) and 2/29 (7%)
(p = 0.007) respectively. The favourable group also showed an improved PFS (8 months vs. 3 months, p < 0.0001)
and OS (15 months vs. 6 months, p < 0.0001).
Conclusions: Our results suggest that prospective selection of optimal candidates for cetuximab treatment is
feasible and may be able to improve clinical outcome.
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The RAS (K-RAS and N-RAS) molecular testing repre-
sented a further step towards a more accurate selection
of metastatic colorectal cancer patients clinically candi-
dates to receive treatment with anti-EGFR monoclonal
antibodies. Data from recent first-line trials strengthened
the idea that anti-EGFR targeted agents could positively
affect natural history of metastatic colorectal cancer but
only when the appropriate clinical and molecular selec-
tion is applied [1-6].* Correspondence: marioscartozzi@gmail.com
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unless otherwise stated.As a consequence we are now able to exclude from
anti-EGFR treatment more patients with potentially re-
fractory colorectal tumours, but on the other hand we
are still unable to select responding patients among
those presenting with a RAS wild type status. In fact
clinical observations suggested that a large proportion of
patients, ranging from 40% to 60%, did not benefit from
the use of anti-EGFR targeted antibodies although in the
absence of a K-RAS/N-RAS mutation and are then ex-
posed to unnecessary toxicity [7,8].
The main beyond-RAS research areas explored in the
attempt to improve patients’ selection focused on the
EGFR itself, the EGFR-downstream signalling pathway
and the interaction between other receptors such as theral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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EGFR gene copy number (GCN) correlated with clinical
outcome during anti-EGFR treatment in colorectal cancer
patients. Many factors prevented the use of the EGFR
GCN into clinical practice, particularly the inconsistency
of different cut-off values from different studies [9-12].
Translational findings about growth factors receptors
interdependence supported the hypothesis that HER-3 and
the Insulin-like growth factor-1 (IGF-1) might affect the
biological activity of the EGFR through a molecular inter-
ference with the EGFR lateral signalling ultimately deter-
mining resistance to anti-EGFR treatment [13-16]. Among
other biological factors affecting the EGFR downstream
pathway B-RAF mutational status and, t a lesser extent,
PIK3CA mutational status resulted strongly implicated.
Many analyses indicated that B-RAF mutation might
have a prognostic role although with an uncertain pre-
dictive value. Therefore the use of B-RAF for anti-EGFR
treatment is indefinite and mainly based on clinicians
judgement [17-21]. Notably the proportion of colorectal
cancer patients potentially presenting with a B-RAF gene
mutation is not negligible (about 10-15% in a K-RAS
wild type population) and even proportionally increasing
in an all-RAS wild type population.
Currently also mutations at exon 20 of PIK3CA, al-
though rarely found in colorectal cancer patients (less than
5% in most studies) have been demonstrated to determine
resistance to anti-EGFR monoclonal antibodies [19].
Although promising, none of these molecular markers
entered clinical practice mainly because of the lack of a
prospective validation.
The aim of our study was to evaluate whether a panel
of molecular biomarkers including EGFR GCN, HER-3,
IGF-1, B-RAF and PIK3CA prospectively analysed at the
start of treatment, might be able to predict colorectal
cancer patients clinical outcome during second- third-line
treatment with cetuximab in combination with chemo-
therapy more accurately than RAS status alone.
Patients and methods
Patients selection and study design
All study procedures have been approved by our institu-
tional review board (Institutional Review Board of the
University Hospital of Ancona, Polytechnic University of
the Marche, Ancona, Italy). Patients with histologically
proven K-RAS wild type metastatic colorectal cancer,
with clinical indication to receive second or third-line
treatment with cetuximab in combination with chemo-
therapy were eligible for our study. After the introduc-
tion of N-RAS analysis only RAS wild type patients were
considered for the study and all patients already in-
cluded were re-analysed for N-RAS mutations. All con-
secutive patients with confirmed diagnosis of metastatic
colorectal cancer were screened after signing informedconsent to study procedure. All patients enrolled had
measurable metastatic disease. Other inclusion/exclusion
criteria were those commonly applied in prospective tri-
als (i.e. adequate liver and renal function, age > 18 years).
Our primary aim was to verify whether a beyond RAS
prospective molecular selection was able to improve
patients outcome in terms of response rate (RR, primary
endpoint of the study). Patients were prospectively allo-
cated into 2 groups on the basis of their biomarkers pro-
file: favourable (BRAF V600E and PIK3CA exon 20 wild
type, EGFR FISH GCN ≥ 2.6, HER-3 Rajkumar score ≤ 8,
IGF-1 immunostaining < 2) and unfavourable (any of the
previous markers altered or mutated). To detect a differ-
ence in terms of RR among patients with an unfavour-
able profile (estimated around 25%) and patients with a
favourable profile (estimated around 60%), with a prob-
ability alpha of 0.05 and beta of 0.05, required sample
size was 46 patients. Response rate was evaluated every
8 weeks according to the Response Evaluation Criteria
in Solid Tumours (RECIST, v. 1.1) by treating physicians
who were blind to biomarkers results and prognostic
group allocation.
Secondary endpoints were progression free survival (PFS)
and overall survival (OS)
Overall survival and progression-free survival were defined
respectively as the interval between the start of cetuximab
and irinotecan therapy to death or last follow-up visit and
as the interval between the start of cetuximab and irino-
tecan therapy to clinical progression or death or last
follow up visit if not progressed.Study design is depicted
in Figure 1.
Statistical analysis was performed with MedCalc soft-
ware version 10.4.8 for Windows.The association be-
tween categorical variables was estimated by chi square
test. Survival probability over time was estimated by the
Kaplan–Meier method. Significant differences in the
probability of survival between the strata were evaluated
by log-rank test.
K-RAS mutational analysis
The variants of codons 12, 13, 59, 61, 117 and 146 of the
K-RAS gene (G12D, G12A, G12V, G12S, G12R, G12C,
G13D, G13C in exon 2; A59P, A59T, A59S, A59G, A59E,
A59V, Q61K, Q61E, Q61R, Q61L, Q61P, Q61H in exon
3; K117Q, K117E, K117T, K117I, K117R, K117N, A146P,
A146T, A146S, A146G, A146E, A146V in exon 4) have
been analysed via pyrosequencing using the “Anti-EGFR
MoAb response kit (KRAS status) (Diatech Pharmaco-
genetics., Italy).
N-RAS mutational analysis
The variants of codons 12, 13, 58, 59, 61, 117 and 146 of
the N-RAS gene (G12D, G12A, G12V, G12S, G12R,
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Figure 1 Study design. K-RAS (and then RAS) wild type colorectal cancer patients candidates to receive treatment with cetuximab were prospectively
assigned to the favourable or unfavourable group on the basis of their molecular profile. All patients were then treated with cetuximab in combination
with chemotherapy. Treating physicians were blind to patients allocation. RR was the primary endpoint of the study.
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2; T58A, T58P, T58S, T58I, A59P, A59T, A59S, A59G,
A59D, A59V, Q61K, Q61E, Q61R, Q61L, Q61P, Q61H
in exon 3; K117Q, K117E, K117T, K117M, K117R,
K117N,A146P, A146T, A146S, A146G, A146D e A146V
in exon4.) have been analysed via pyrosequencing using
the “Anti-EGFR MoAb response kit (N-RAS status)
(Diatech Pharmacogenetics, Italy).
B-RAF mutational analysis
The variants of codons 464, 466, 469, and 600
(G464V, G464E, G466V, G466A, G466E, G466R,
G469V, G469A, G469E, G469R in exon 11 and V471F,
T599I, V600E, K601E, V600M in exon 15) have been ana-
lysed via pyrosequencing using the “Anti-EGFR MoAb
response kit (BRAF status) (Diatech Pharmacogenetics,
Italy). Only the V600E mutation was considered rele-
vant to study procedure.
PIK3CA mutational analysis
The variants of codons 542, 545, 546 1043, 1047 and 1049
(E542K, E545K, E545A, E545G, Q546K, Q546E in exon 9
and M1043I, H1047Y, H1047R, H1047L, G1049R and
G1049S in exon 20) have been analysed via pyrosequenc-
ing using the “Anti-EGFR MoAb response kit (PIK3CA
status) (Diatech Pharmacogenetics, Italy). Only mutations
in exon 20 were considered relevant to study procedure
HER-3 expression
HER-3 was evaluated with an immunohistochemical
technique on 3–5 μm thick tissue sections obtainedfrom paraffin-embedded using the monoclonal mouse
antibody anti-human HER-3 (DAK-H3-IC) as previously
described.
The stained slides were evaluated according to the
Rajkumar score. The cut-off point with the highest sen-
sitivity and specificity for estimating HER-3 expression
was set at ≤ 8 according to previous reports [13,21].IGF-1 expression
IGF-1 was evaluated with an immunohistochemical
technique on 3–5 μm thick tissue sections obtained
from paraffin-embedded samples using the rabbit poly-
clonal antibody raised against amino acids 49–118 of
IGF-1 of human origin, (Santa Cruz Biotechnology) as
previously reported.
IGF-1 expression was estimated by semi -quantitative
analysis and classified into one of four grades. The
tumour was defined positive for IGF-1 expression when
the grade of the immunostaining was ≥ 2, according to
previous reports [14,21].Fluorescence in situ hybridization analysis for EGFR gene
copy number
Fluorescence in situ hybridization (CISH) for the EGFR
gene was performed using the standard dual-colour
EGFR Spectrum Orange™/CEP7® Spectrum Green™ probe
(Visys, Downers Grove, IL USA). The cut-off point with
the highest sensitivity and specificity for estimating
FISH EGFR GCN was set at 2.6 according to previous
reports [9,21].
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From April 2012 to May 2014, 46 patients were enrolled,
30 males (65%) and 16 females (35%), median age at
study entry was 67 years. Most of the patients had an
Eastern Cooperative Oncology Group Performance Sta-
tus (ECOG PS) 0 or 1 (29 patients, 63%) and 2 or more
metastatic sites (39 patients, 85%). Thirty-six patients
(78%) received at least 2 previous lines of treatment. In
the whole population we observed 13 partial remissions
(26%), median PFS was 3.3 months and median OS was
11 months. Main patients’ characteristics have been
summarised in Table 1. Overall we found 2 BRAF
V600E mutations (4%) and 3 PIK3CA exon 20 muta-
tions (6%). The remaining patients were wild type for
either B-RAF or PIK3CA mutational status. EGFR FISH
GCN was ≥ 2.6 in 28 patients (61%), HER-3 RajkumarTable 1 Patients characteristics and main study results accord
Whole group
(n = 46)
Age (range) 67 (36–81)
Sex
Males 30 (65%)
Females 16 (35%)
ECOG PS
0-1 29 (63%)
2-3 17 (47%)
Metastatic sites
1 7 (15%)
≥ 2 39 (85%)
Previous lines of treatment
1 10 (22%)
≥ 2 36 (78%)
Treatment
FOLFIRI/Cet 9 (19%)
Irinotecan/Cet 37 (81%)
Response rate
PR 13 (26%)
SD 6 (16%)
DCR (PR + SD) 19 (41%)
PD 27 (59%)
Survival
PFS(months) 3.3
OS (months) 11
ECOG PS = Eastern Cooperative Oncology Group Performance Status.
FOLFIRI = Fluorouracil, leucovorin, Irinotecan.
Cet = Cetuximab.
PR = Partial Response.
SD = Stable Disease.
DCR = Disease Control Rate.
PD = Progressive Disease.score was ≤ 8 in 25 patients (56%), IGF-1 immunostain-
ing was < 2 in 30 patients (65%) (Table 2).
N-RAS analysis of patients enrolled before the intro-
duction of N-RAS wild type status as a further pre-
requisite for anti-EGFR treatment (35 patients) revealed
1 N-RAS mutation (3%) in a patient allocated to the un-
favourable group because of HER-3 over-expression.
According to biomarkers results 17 patients (37%) were
prospectively allocated to the favourable group and 29
patients (63%) were prospectively allocated to the
unfavourable group. Main clinical characteristics (age,
sex, ECOG PS, previous treatments, number of meta-
static sites) resulted comparable between the 2 groups
(favourable vs. unfavourable) (Table 1). Patients with
the unfavourable profile showed 2 BRAF mutations, 3
PIK3CA exon 20 mutations, 18 cases of FISH EGFRing to the 2 study groups (unfavourable and favourable)
Unfavourable Favourable p value
(n = 29) (n = 17)
66 (36–79) 67 (38–81) ns
21 (72%) 9 (53%) ns
8 (28%) 7 (47%) ns
18 (62%) 11 (65%) ns
11 (38%) 6 (35%) ns
5 (17%) 2 (12%) ns
24 (83%) 15 (88%) ns
6 (21%) 4 (9%) ns
23 (89%) 15 (88%) ns
6 (21%) 3 (23%) ns
23 (79%) 14 (77%) ns
2 (7%) 11 (65%) 0.007
3 (10%) 3 (18%) 0.8
5 (17%) 14 (82%) 0.0001
24 (83%) 3 (18%) 0.0001
3 8 < 0.0001
6 15 < 0.0001
Table 2 Results for molecular markers analysed
Whole group (n = 46)
BRAFV600E
Mut 2 (4%)
Wild Type 44 (96%)
PIK3CA exon 20
Mut 3 (6%)
Wild Type 43 (94%)
EGFR FISH GCN
<2.6 18 (39%)
≥2.6 28 (61%)
HER 3 IHC Score
>8 20 (44%)
≤8 26 (56%)
IGF-1 IHC Score
≥2 16 (35%)
<2 30 (65%)
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overexpression respectively.
In the favourable group we observed 11 patients (65%)
with a partial response (PR), whereas in the unfavourable
group only 2 patients (7%) showed a PR (p = 0.007).
Disease control rate (DCR) resulted also improved in
the favourable group (82% vs. 17%, p = 0.0001). Accord-
ingly only 3 patients (18%) in the favourable group and
as much as 24 patients (83%) in the unfavourable group
progressed during treatment (p = 0.0001) (Table 1).Figure 2 Median progression-free survival (PFS) results. Kaplan-Meier curve
and cetuximab prospectively allocated in the unfavourable (-------) and favMedian PFS was 8 months in the favourable group,
whereas it was 3 months in the favourable group (p <
0.0001) (Figure 2). Median OS in the favourable and un-
favourable group was 15 months vs. 6 months respect-
ively (p < 0.0001) (Figure 3).Discussion
Many years after the introduction of anti-EGFR mono-
clonal antibodies the debate about the optimal molecular
and clinical selection is more current than ever. Al-
though the introduction of RAS mutational analysis im-
proved our ability to exclude resistant patients, there is
still a clear clinical need of further refining the selection
process.
At present the beyond RAS molecular selection for
monoclonal antibodies directed against the EGFR is one
of the most actively investigated topic. However the final
impact on clinical practice of research findings appears
clearly not proportionate to the vast amount of data
produced.
We suggest that a beyond-RAS prospective selection is
feasible and potentially effective in further identifying
optimal candidates for anti-EGFR treatment. We believe
that the observed 65% response rate observed in the
favourable group might be of great interest particularly
in a pre-treated population where RR with anti-EGFR
monoclonal antibodies is usually reported at around 20-
40% (depending on the treatment line). Accordingly the
disappointing RR found in the unfavourable group (7%)
is a suggestion of an inadequate clinical activity in this
group of RAS wild type patients.s for median PFS of colorectal cancer patients treated with irinotecan
ourable (———) arm (3 months vs. 8 months, p < 0.0001).
Figure 3 Median overall survival (OS) results. Kaplan-Meier curves for median OS of colorectal cancer patients treated with irinotecan and cetuximab
prospectively allocated in the unfavourable (-------) and favourable (———) arm (6 months vs. 15 months, p < 0.0001).
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enriched study is in line with the study hypothesis and
comparable with results from retrospective studies in-
vestigating these biological markers [22].
In retrospective series response rate for K-RAS wild
type patients showing HER-3 and IGF-1 negative tu-
mours ranged in fact from 50 to 65%. Similarly a re-
sponse rate ranging from 30 to 88% was observed
among patients with increased EGFR GCN.
On the contrary several analyses were concordant in
fixing at around 0% the RR for B-RAF mutant tumours
[18-20]. Very similar figures have been reported for
PIK3CA mutant tumours [19].
Although survival parameters were not primary aims
of our study, we also suggested that a more accurate
molecular selection might have a significant impact also
on PFS and OS.
The effect on PFS and OS was however less pro-
nounced than that reported in previous retrospective
analyses. The prospective selection itself might have
reduced the magnitude of the overall survival results
observed in retrospective studies. More importantly the
study was not designed to detect a difference in median
PFS or OS and therefore survival results are merely
speculative.
Conclusions
The present study represents the proof of principle that
a prospective molecular selection is feasible and clinic-
ally relevant. On the one hand we demonstrated that a
beyond-RAS molecular profile might improve the thera-
peutic efficacy of cetuximab in the favourable group ofpatients, while on the other hand we also suggested that
in the unfavourable group of patients anti-EGFR strat-
egies are ineffective. This implies that different treat-
ment options should be pursued in these patients.
A straightforward interpretation of our findings should
be regarded as scientifically difficult. At this point it is
not in fact possible to define the individual and inde-
pendent role of each biological variable analysed. The
patients’ number was clearly not planned for this aim
and it is inadequate for further speculations.
At our knowledge this is the first prospectively de-
signed study with the specific aim to define the role of a
molecular profile in metastatic colorectal cancer patients
receiving cetuximab.
As our patients’ expectations are understandingly in-
creasing, any effort should be made in order to move
from retrospective to prospective and ultimately into
practice in order to maximise efficacy and avoid un-
necessary toxicities.
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